Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | STAT1 | P42224 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30952890 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2L3MBTL1GAACHRNB2CHRNA4 | |
| SCHEMBL23625934 | 0.77 | CYP2D6 (0.32) | — | |
| SCHEMBL25995484 | 0.77 | L3MBTL1 (0.38) | SMN1; SMN2L3MBTL1GAACHRNB2CHRNA4 | |
| SCHEMBL24961373 | 0.76 | CNR2 (0.43) | — | |
| SCHEMBL30040347 | 0.76 | CNR2 (0.43) | — | |
| SCHEMBL28765821 | 0.74 | SMN1; SMN2 (0.39) | SMN1; SMN2L3MBTL1GAACHRNB2CHRNA4 | |
| SCHEMBL24823325 | 0.74 | — | — | |
| SCHEMBL30310958 | 0.74 | — | — | |
| SCHEMBL30195000 | 0.74 | L3MBTL1 (0.36) | SMN1; SMN2L3MBTL1GAACHRNB2CHRNA4 | |
| SCHEMBL30040160 | 0.71 | CNR2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113767090-B | Tricyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230021669-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2023-01-26 | — | — | US | disclosed |
| CN-113767090-A | Tricyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2021-12-07 | — | — | CN | disclosed |
| WO-2021136244-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021669-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP4A11, CYP4F11, CYP11B2 | SMN1; SMN2 3789/4885L3MBTL1 1724/4885GAA 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.